Trials / Completed
CompletedNCT06493409
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of coadministration of voriconazole or quinidine on the pharmacokinetics (PK) of repotrectinib in healthy male and female (individual not of childbearing potential \[INOCBP\]) participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Repotrectinib | Specified dose on specified days |
| DRUG | Voriconazole | Specified dose on specified days |
| DRUG | Quinidine | Specified dose on specified days |
Timeline
- Start date
- 2024-08-26
- Primary completion
- 2024-12-07
- Completion
- 2024-12-07
- First posted
- 2024-07-10
- Last updated
- 2025-08-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06493409. Inclusion in this directory is not an endorsement.